Because many different cell types express the IL-21R, systemic IL-21 treatment may not only act on LSCs but most likely will also affect other IL-21R-expressing cell types such as CD8+ T cells and natural killer (NK) cells and may therefore improve the immune control of AML. The gene discussed is CD8A; the disease is acute myeloid leukemia.